Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo
Open Access
- 3 October 2006
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 95 (9), 1212-1219
- https://doi.org/10.1038/sj.bjc.6603367
Abstract
The unique properties of the tumour microenvironment can be exploited by using recombinant anaerobic clostridial spores as highly selective gene delivery vectors. Although several recombinant Clostridium species have been generated during the past decade, their efficacy has been limited. Our goal was to substantially improve the prospects of clostridia as a gene delivery vector. Therefore, we have assessed a series of nitroreductase (NTR) enzymes for their capacity to convert the innocuous CB1954 prodrug to its toxic derivative. Among the enzymes tested, one showed superior prodrug turnover characteristics. In addition, we established an efficient gene transfer procedure, based on conjugation, which allows for the first time genetic engineering of Clostridium strains with superior tumour colonisation properties with high success rates. This conjugation procedure was subsequently used to create a recombinant C. sporogenes overexpressing the isolated NTR enzyme. Finally, analogous to a clinical setting situation, we have tested the effect of multiple consecutive treatment cycles, with antibiotic bacterial clearance between cycles. Importantly, this regimen demonstrated that intravenously administered spores of NTR-recombinant C. sporogenes produced significant antitumour efficacy when combined with prodrug administration.Keywords
This publication has 31 references indexed in Scilit:
- Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expressionGene Therapy, 2005
- Effect of hypoxia on Ad5 infection, transgene expression and replicationGene Therapy, 2005
- Clostridia in cancer therapyNature Reviews Microbiology, 2003
- Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicumCancer Gene Therapy, 2001
- Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954Cancer Gene Therapy, 2000
- Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironmentGene Therapy, 1997
- Chemotherapeutic tumour targeting using clostridial sporesFEMS Microbiology Reviews, 1995
- Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12FEMS Microbiology Letters, 1994
- Conjugative plasmid transfer from Escherichia coli to Clostridium acetobutylicumJournal of General Microbiology, 1990
- Clostridial oncolysis in manEuropean Journal of Cancer (1965), 1967